Plasminogen activator inhibitor type 1: physiology and role in renal pathophysiology

被引:0
|
作者
Rerolle, JP [1 ]
Vigneau, C [1 ]
Hertig, A [1 ]
Berrou, J [1 ]
Rondeau, E [1 ]
机构
[1] Hop Tenon, Serv Nephrol A, INSERM, U489, F-75970 Paris 20, France
来源
NEPHROLOGIE | 2001年 / 22卷 / 01期
关键词
PAI-1; cellular mobility; fibrosis; kidney;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor type 1 plays a prominant part in the regulation of extra and intra-vascular fibrinolysis through the inhibition of plasmin formation. In addition to its role in the resolution of blood clots, PAI-1 is involved in a variety of other biological processes including extracellular remodeling, cellular mobility, embryo implantation, development and tumoral proliferation. Moreover, PAI-1 is also implicated in various pathological processes such as thromboembolic diseases, atherosclerosis and fibrosis formation, particulary in the kidney and the lung. Inhibition of PAI-1 activity or of PAI-1 synthesis by specific antibodies, peptidic antagonists, antisens oligonucleotides or decoy oligonucleotides has been obtained in vitro but need to be evaluated in vivo. All these findings may have new therapeutical implications, explaining the importance of studies on PAI-1 production and regulation.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 50 条
  • [31] Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases
    Anne-lie Ståhl
    Karl Johansson
    Maria Mossberg
    Robin Kahn
    Diana Karpman
    Pediatric Nephrology, 2019, 34 : 11 - 30
  • [32] Molecular basis of circadian rhythmicity in renal physiology and pathophysiology
    Gumz, Michelle L.
    EXPERIMENTAL PHYSIOLOGY, 2016, 101 (08) : 1025 - 1029
  • [33] Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases
    Stahl, Anne-lie
    Johansson, Karl
    Mossberg, Maria
    Kahn, Robin
    Karpman, Diana
    PEDIATRIC NEPHROLOGY, 2019, 34 (01) : 11 - 30
  • [34] Renal Manifestations of Covid-19: Physiology and Pathophysiology
    Armaly, Zaher
    Kinaneh, Safa
    Skorecki, Karl
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 24
  • [35] Effect of growth hormone on plasminogen activator and inhibitor activity in rat
    Bubber P.
    Sharma A.
    Chauhan A.
    Bansal D.D.
    Indian Journal of Clinical Biochemistry, 2013, 28 (2) : 193 - 196
  • [36] Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production
    Siddiquee, Khandaker
    Hampton, Jessica
    Khan, Susan
    Zadory, Dan
    Gleaves, Linda
    Vaughan, Douglas E.
    Smith, Layton H.
    JOURNAL OF HYPERTENSION, 2011, 29 (04) : 724 - 731
  • [37] Plasminogen Activator Inhibitor-1 Is a Transcriptional Target of the Canonical Pathway of Wnt/β-Catenin Signaling
    He, Weichun
    Tan, Ruoyun
    Dai, Chunsun
    Li, Yingjian
    Wang, Dan
    Hao, Sha
    Kahn, Michael
    Liu, Youhua
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (32) : 24665 - 24675
  • [38] Plasminogen Activator Inhibitor-1 as a Marker of Esophageal Functional Changes in Pediatric Eosinophilic Esophagitis
    Williamson, Prerana
    Proudfoot, James
    Gharibans, Armen
    Dohil, Lucas
    Newbury, Robert
    Barsamian, Jacqueline
    Hassan, Maheen
    Rawson, Renee
    Katzka, David
    Kurten, Richard
    Dohil, Ranjan
    Mousa, Hayat
    Aceves, Seema
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (01) : 57 - +
  • [39] RETRACTED: Role of guanine-nucleotide exchange factor Epac in renal physiology and pathophysiology (Retracted Article)
    Yang, Shi-kun
    Xiao, Li
    Li, Jun
    Liu, Fuyou
    Sun, Lin
    Kanwar, Yashpal S.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 304 (07) : F831 - F839
  • [40] RENAL SYNTHESIS OF ATRIOPEPTIN-LIKE PROTEIN IN PHYSIOLOGY AND PATHOPHYSIOLOGY
    GREENWALD, JE
    NEEDLEMAN, P
    WILKINS, MR
    SCHREINER, GF
    AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (04): : F602 - F607